Search This Blog

Monday, January 11, 2021

Clovis Oncology Has Prelim Q4, 2020 Product Revenues

 

  • Estimated $43.0M - $43.5M in Rubraca® (rucaparib) global sales for Q4 2020 and $164.2M - $164.7M for FY 2020

  • Q4/FY 2020 Operating Results call planned for February 23, 2021

  • Company to present at J.P. Morgan Healthcare Conference on Tuesday, January 12

 A live webcast of the presentation/Q&A session can be accessed through the investor relations section of the Company’s website at clovisoncology.com. Approximately 24 hours following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.